So I found this online. I see my oncologist tomorrow but want to prepare myself. It looks like tumors in my liver, lung and abdomen lit up?
Thanks for any help anyone can give in making sense of this.
COMPARISON EXAMINATION: CT of the chest report dated 05/22/18,
CT of the abdomen and pelvis report dated 09/06/18
INDEX LESION SIZE SUV INTERPRETATION
Right lower posteromedial hemithorax pulmonary parenchyma, right
lower lobe (n=2) 11.6-mm (largest) (frame 200) 5.5 (max)
Fulfills quantitative criteria for viable neoplasm
Right lobe hepatic parenchyma segment VIII 52.8 x 51.9-mm(frame 187) 7.3 ratio > 2.0 Fulfills quantitative criteria
for viable neoplasm
Abdominal retroperitoneum and mesentery, abdominal wall 36.9 x33.1-mm (largest) (Frame 169) 8.5 (max) Fulfills quantitative criteria for viable neoplasm
TECHNIQUE: Following the intravenous administration of 11.4
mCi of F-18 deoxyglucose via the left antecubital fossa,
multiplanar image acquisitions of the neck, chest, abdomen and pelvis to level of mid thigh, obtained at one hour post radiopharmaceutical administration contemporaneously interpretedwith the current CT of the neck, chest, abdomen and pelvis tolevel of mid thigh, dated 09/18/18 via coregistration and CT of
the chest report dated 05/22/18, CT of the abdomen and pelvisreport dated 09/06/18 reveal:
SERUM GLUCOSE LEVEL: 92 mg/dl.
1. Focal increased glucose concentration is observed in the right lower posteromedial hemithorax pulmonary parenchyma, rightlower lobe in two separate nodular presentations. The correctedmaximum calculated standard uptake value is 5.5. The maximal
axial diameter of the largest, most conspicuous density on
review of CT of the thorax dated 09/18/18 is 11.6-mm
2. Heterogeneous increased radiotracer uptake is manifest in
the superior aspect of the right lobe of the liver (3.
involving segment VIII generating a corrected maximum calculated
standard uptake value of 7.3, with a lesion to liver background
ratio greater than 2.0. The maximal axial diameter of the
corresponding metabolic, morphologic abnormality on review of CT
of the abdomen dated 09/18/18 is 52.8-mm (transverse) x 51.9-mm
3. Multifocal increased FDG concentration is defined in the
abdominal retroperitoneum and mesentery, the midline lower
anterior, left mid anterolateral abdominal wall. The corrected
maximum calculated standard uptake value is 8.5. The maximal
axial diameter of the largest individual metabolic, morphologic
abnormality on review of CT of the abdomen and pelvis dated
09/18/18 is 36.9-mm (transverse) x 33.1-mm (AP).
4. Normal physiologic distribution of the radiopharmaceutical
is apparent in the splenic parenchyma, both renal units, bladder
and visualized intestinal tract. The visualized portion of the
cerebral cortex demonstrate symmetric and preserved glucose
metabolism. Diffuse radiopharmaceutical concentration is noted
in all four quadrants of the abdomen and pelvis.
Pertinent CT findings are as follows: CHEST: Bilateral
subcentimeter axillary soft tissue densities are non-glucose
avid. There are no parenchymal densities-nodules noted in the
right-left hemithorax demonstrating discernible quantitatively
significant increased glucose metabolism. A subcentimeter
non-calcified density noted in the right lower lateral lung
field is ametabolic. ABDOMEN AND PELVIS: The gallbladder is
surgically absent. Postsurgical changes are defined in the left
anterior abdominal mesentery without focal increased glucose
metabolism. Subcentimeter bilateral axillary soft tissue
densities are non-glucose avid. Calcifications are defined in
the bilateral lower hemipelvis. SKELETAL: Degenerative
changes are noted in the cervical, thoracic and lumbar spine.
ORDER #: 0918-0010 PET/PET CT skull midthigh initial
1. ABNORMAL EXAMINATION INDICATIVE OF MALIGNANT VIABLE
2. Increased glucose concentration demonstrated in the right
lower medial hemithorax pulmonary parenchyma, right lower lobe,
fulfills quantitative criteria for viable neoplasm. (Gould et
al, Annals of Internal Medicine, 138:724, 2003).
3. Viable neoplastic transformation appears evident in the
right lobe of the hepatic parenchyma involving segment VIII.
4. Facilitated radiopharmaceutical concentration noted in the
abdominal retroperitoneum and mesentery, the anterior abdominal
wall, fulfills quantitative criteria for viable neoplasm.